- Sally Susman, Pfizer's EVP, is set to depart after 18 years, aligning with strategic shifts.
- Wall Street analysts project a potential increase in Pfizer's stock price with a notable upside of 11.26%.
- The consensus brokerage recommendation for Pfizer remains at a “Hold” status with a GF Value indicating moderate growth potential.
Pfizer Inc. (PFE), a global leader in biopharmaceuticals, has announced the upcoming departure of its Executive Vice President, Sally Susman. After 18 transformative years, Susman played a crucial role in fostering stakeholder relations and spearheading key campaigns. Her exit is part of Pfizer’s ongoing strategy to seamlessly integrate Corporate Affairs into its core business units. Susman will remain with the company to ensure a smooth transition through 2025.
Wall Street Analysts' Forecasts
In the realm of stock performance, 21 analysts have set their sights on Pfizer Inc. (PFE), providing one-year price targets that suggest interesting opportunities for investors. The average target price is currently $28.67, with forecasts ranging from a low of $23.00 to a high of $41.49. This average presents a potential upside of 11.26% from the current share price of $25.77. For a comprehensive view of these estimates, visit the Pfizer Inc (PFE, Financial) Forecast page.
The consensus recommendation from 25 brokerage firms for Pfizer Inc. (PFE) is firmly positioned at 2.6, indicating a "Hold" status. This rating is on a scale from 1, representing a Strong Buy, to 5, representing a Sell.
According to GuruFocus metrics, the projected GF Value for Pfizer in one year is estimated at $27.27. This suggests a potential upside of 5.84% from the current trading price of $25.765. The GF Value is calculated by analyzing historical multiples, past business growth, and future business performance estimates. For further insights, visit the Pfizer Inc (PFE, Financial) Summary page.
